Impact of sleeve gastrectomy and Roux-en-Y gastric bypass on biopsy-proven non-alcoholic fatty liver disease

Cherla, Deepa V.; Rodriguez, Noe A; Vangoitsenhoven, Roman; Singh, Tavankit; Mehta, Neal; McCullough, Arthur J.; Brethauer, Stacy A.; Schauer, Philip R.; Aminian, Ali

doi:10.1007/s00464-019-07017-0

Cited by 39 publications

(35 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 84% of the patients, liver function test values were normalised following bariatric surgery by the end of the first postoperative year. Hereby, both RYGB and SG proved to be similarly effective [39]. RYGB and SG surgery also significantly improved alanine aminotransferase, aspartate aminotransferase, NAFLD activity score and NAFLD fibrosis score [37].…”

Section: Impact Of Gastric Bypass Surgery On Gut Microbiotamentioning

confidence: 69%

Microbial Adaptation Due to Gastric Bypass Surgery: The Nutritional Impact

2020

View full text Add to dashboard Cite

Bariatric surgery leads to sustained weight loss and the resolution of obesity-related comorbidities. Recent studies have suggested that changes in gut microbiota are associated with the weight loss induced by bariatric surgery. Several studies have observed major changes in the microbial composition following gastric bypass surgery. However, there are inconsistencies between the reported alterations in microbial compositions in different studies. Furthermore, it is well established that diet is an important factor shaping the composition and function of intestinal microbiota. However, most studies on gastric bypass have not assessed the impact of dietary intake on the microbiome composition in general, let alone the impact of restrictive diets prior to bariatric surgery, which are recommended for reducing liver fat content and size. Thus, the relative impact of bariatric surgery on weight loss and gut microbiota remains unclear. Therefore, this review aims to provide a deeper understanding of the current knowledge of the changes in intestinal microbiota induced by bariatric surgery considering pre-surgical nutritional changes.

show abstract

Section: Impact Of Gastric Bypass Surgery On Gut Microbiotamentioning

confidence: 69%

Microbial Adaptation Due to Gastric Bypass Surgery: The Nutritional Impact

2020

View full text Add to dashboard Cite

show abstract

“…In a separate prospective cohort study on 94 patients who underwent sleeve gastrectomy with biopsy proven NAFLD at the time of index operation had a statistically significant decrease in steatosis grade, hepatocyte ballooning, lobular infiltration, and fibrosis stage on follow-up biopsy performed a year following surgery [51]. Importantly, other investigators have reported that sleeve gastrectomy and Roux-En-Y gastric bypass are similarly effective at improving liver function [50], allowing the bariatric surgeon evaluating a patient with NAFLD/NASH to choose the procedure best suited for their specific patient.…”

Section: Prevention Of Nafld/nash Associated Primary Liver Cancermentioning

confidence: 96%

“…Current treatment of NAFLD and NASH consists of lifestyle modification, weight loss via diet and exercise, and bariatric surgery. Bariatric surgery is safe, provides durable weight loss, and reverses or improves many end-organ complications of metabolic syndrome, particularly type 2 diabetes [45][46][47][48][49][50][51]. The two most commonly performed bariatric procedures in the United States are laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass.…”

Section: Prevention Of Nafld/nash Associated Primary Liver Cancermentioning

confidence: 99%

Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery

Selby

Ejaz

Brethauer

et al. 2020

Expert Opinion on Investigational Drugs

Self Cite

View full text Add to dashboard Cite

“…A meta-analysis showed that BS can significantly reduce mortality and expand lifetime in adults with obesity compared to usual obesity management [ 102 ]. The bariatric procedures sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) on NAFLD and NASH are similarly effective, evidenced by the change of liver function tests (LFTs) after one year of surgery [ 103 ]. Other studies indicate that there are some differences induced by BS procedures [ 104 , 105 ].…”

Section: Treatment Options For Nafld and Nashmentioning

confidence: 99%

Current Options and Future Directions for NAFLD and NASH Treatment

Zhang

Yang

2021

IJMS

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, with a broad spectrum ranging from simple steatosis to advanced stage of nonalcoholic steatohepatitis (NASH). Although there are many undergoing clinical trials for NAFLD treatment, there is no currently approved treatment. NAFLD accounts as a major causing factor for the development of hepatocellular carcinoma (HCC), and its incidence rises accompanying the prevalence of obesity and diabetes. Reprogramming of antidiabetic and anti-obesity medicine is a major treatment option for NAFLD and NASH. Liver inflammation and cellular death, with or without fibrosis account for the progression of NAFLD to NASH. Therefore, molecules and signaling pathways involved in hepatic inflammation, fibrosis, and cell death are critically important targets for the therapy of NAFLD and NASH. In addition, the avoidance of aberrant infiltration of inflammatory cytokines by treating with CCR antagonists also provides a therapeutic option. Currently, there is an increasing number of pre-clinical and clinical trials undergoing to evaluate the effects of antidiabetic and anti-obesity drugs, antibiotics, pan-caspase inhibitors, CCR2/5 antagonists, and others on NAFLD, NASH, and liver fibrosis. Non-invasive serum diagnostic markers are developed for fulfilling the need of diagnostic testing in a large amount of NAFLD cases. Overall, a better understanding of the underlying mechanism of the pathogenesis of NAFLD is helpful to choose an optimized treatment.

show abstract

Impact of sleeve gastrectomy and Roux-en-Y gastric bypass on biopsy-proven non-alcoholic fatty liver disease

Cited by 39 publications

References 24 publications

Microbial Adaptation Due to Gastric Bypass Surgery: The Nutritional Impact

Microbial Adaptation Due to Gastric Bypass Surgery: The Nutritional Impact

Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery

Current Options and Future Directions for NAFLD and NASH Treatment

Contact Info

Product

Resources

About